| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| REYNO LEONARD | Chief Medical Officer | C/O C4 THERAPEUTICS, INC., 490 ARSENAL WAY #120, WATERTOWN | /s/ Shagha Russell, Attorney-in-Fact | 18 Feb 2026 | 0001528716 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | CCCC | Common Stock | Award | $0 | +240,000 | +153% | $0.000000 | 396,382 | 13 Feb 2026 | Direct | F1 |
| transaction | CCCC | Common Stock | Options Exercise | $0 | +30,950 | +8.5% | $0.000000 | 396,382 | 14 Feb 2026 | Direct | F2 |
| transaction | CCCC | Common Stock | Tax liability | $31,334 | -16,579 | -4.2% | $1.89 | 379,803 | 14 Feb 2026 | Direct | F3 |
| Id | Content |
|---|---|
| F1 | Represents restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest as follows: (i) 120,000 RSUs shall vest in three equal annual installments following the grant date, with the first installment vesting on February 13, 2027, and (ii) 120,000 RSUs shall vest in full on February 13, 2029, subject to potential acceleration upon achievement of certain performance milestones. |
| F2 | Reflects the acquisition of shares of Common Stock upon vesting of previously disclosed grants of RSUs. The grants of RSUs were initially reported in Table I of the Forms 4 filed by the Reporting Person on February 14, 2024 and February 18, 2025. |
| F3 | Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a sale by the Reporting Person. |